Want to see TSE:LABS full AI Analyst Report?
LABS Stock Chart & Stats
C$0.08
<C$0.01(6.67%)
At close: 4:00 PM EDT
C$0.08
<C$0.01(6.67%)
Day’s Range― - ―
52-Week RangeC$0.06 - C$0.10
Previous CloseN/A
Volume63.91K
Average Volume (3M)140.40K
Market Cap
C$32.04M
Enterprise ValueC$20.36
Total Cash (Recent Filing)C$9.85M
Total Debt (Recent Filing)C$421.00K
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Nov 16, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding427,177,150
10 Day Avg. Volume72,183
30 Day Avg. Volume140,403
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)0.76
Price to Sales (P/S)0.61
P/FCF Ratio-4.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)C$38.98M
Bulls Say, Bears Say
Bulls Say
Margin And Profitability RecoveryThe combination of a 43% gross margin, sharply lower operating expenses, and two consecutive quarters of positive adjusted EBITDA indicates meaningful operating recovery. If maintained, this improvement can strengthen earnings quality and support a more durable path toward full-year profitability.
International Regulated-market ExpansionGrowth across several regulated international markets broadens MediPharm’s commercial reach beyond Canada and supports a more diversified revenue base. New orders and replenishment activity in France, Brazil, and New Zealand provide potential for continued medical-channel scale over coming quarters.
Low Leverage And Financial FlexibilityA substantial cash balance, virtually no debt, and ownership of valuable production facilities give MediPharm flexibility to fund operations and pursue selective growth. Low leverage also reduces solvency pressure while management works to convert operational gains into sustained cash generation.
Bears Say
TTM Losses And Negative Cash FlowDespite recent quarterly improvement, the trailing business remains unprofitable and does not yet generate positive operating or free cash flow. Continued cash burn can constrain reinvestment and increase reliance on liquidity management until profitability and cash conversion become consistently positive.
Declining Revenue TrendThe decline in trailing revenue shows that recent quarterly momentum has not yet translated into sustained year-over-year growth. Without a durable top-line recovery, margin gains may have limited scale benefits and the company could remain vulnerable to changes in product mix and market demand.
Canadian Medical Reimbursement PressureThe 30% VAC reimbursement reduction directly weakened the Canadian medical channel and demonstrates exposure to policy-driven revenue and pricing changes. Because medical channels represent a large portion of the business, further reimbursement or prescribing shifts could pressure volumes, mix, and margins.
MediPharm Labs News
LABS FAQ
What was MediPharm Labs’s price range in the past 12 months?
MediPharm Labs lowest stock price was C$0.06 and its highest was C$0.10 in the past 12 months.
What is MediPharm Labs’s market cap?
MediPharm Labs’s market cap is C$32.04M.
When is MediPharm Labs’s upcoming earnings report date?
MediPharm Labs’s upcoming earnings report date is Nov 16, 2026 which is in 58 days.
How were MediPharm Labs’s earnings last quarter?
MediPharm Labs released its earnings results on Aug 13, 2026. The company reported C$0 earnings per share for the quarter, beating the consensus estimate of -C$0.003 by C$0.003.
Is MediPharm Labs overvalued?
According to Wall Street analysts MediPharm Labs’s price is currently Overvalued.
Does MediPharm Labs pay dividends?
MediPharm Labs does not currently pay dividends.
What is MediPharm Labs’s EPS estimate?
MediPharm Labs’s EPS estimate is >-0.01.
How many shares outstanding does MediPharm Labs have?
MediPharm Labs has 427,177,150 shares outstanding.
What happened to MediPharm Labs’s price movement after its last earnings report?
MediPharm Labs reported an EPS of C$0 in its last earnings report, beating expectations of -C$0.003. Following the earnings report the stock price went down -6.25%.
Which hedge fund is a major shareholder of MediPharm Labs?
Currently, no hedge funds are holding shares in TSE:LABS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MediPharm Labs
MediPharm Labs Corp. operates as a pharmaceutical entity, specializing in the creation and global commercialization of premium, pharmaceutical-grade cannabis oils, concentrates, and sophisticated derivative products. Its market reach extends across Canada, Australia, Germany, and other international territories. The company manages the full cycle from developing and processing to packaging and distributing a diverse array of cannabis extracts and advanced cannabinoid-based formulations. Furthermore, MediPharm Labs provides auxiliary services including GMP-certified flower procurement, specialized packaging, and comprehensive logistics. This enterprise was established in 2015 and has its corporate headquarters situated in Barrie, Canada.
LABS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong operational and financial recovery: return to profitability, highest adjusted EBITDA since 2019, robust margin expansion, meaningful sequential revenue growth driven by international markets (notably Germany), successful Phase II LiBBY clinical results validating the pharmaceutical platform, and balance sheet strength. Headwinds include a material 30% VAC reimbursement cut that reduced Canadian medical revenue, ongoing pricing pressure and competition in key markets (Germany), and broader prescribing/reimbursement uncertainties. Overall, the positive operational execution, clinical validation, and improved profitability notably outweigh the identified challenges.View all TSE:LABS earnings summaries